MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2023 International Congress

    Pain and quality of life in cervical dystonia

    L. Herrmann, L. Vorbeck, A. Palisi, A. Maurer, S. Lezius, J. Mallwitz, M. Gelderblom, S. Zittel (Hamburg, Germany)

    Objective: To evaluate different aspects of quality of life (QoL) and pain prevalence, characteristics and influencing factors in patients with cervical dystonia (CD) before and…
  • 2023 International Congress

    Persistence, Health Care Resource Utilization, and Costs Among OnabotulinumtoxinA-Treated Patients with Cervical Dystonia in the US

    K. Dashtipour, D. Charles, M. Sadeghi, M. Heath, A. Rava, J. Liu, H. Sun, Y. Dong, J. Lee (Loma Linda, USA)

    Objective: To compare health care resource utilization (HCRU) and costs among patients with cervical dystonia (CD) in the US who are persistent vs nonpersistent with…
  • 2023 International Congress

    Dystonia in the Middle East – The Cleveland Clinic Abu Dhabi Experience

    S. Mansoor, K. Waqar, M. Thomas, S. Mittal (Abu Dhabi, United Arab Emirates)

    Objective: This study aimed to evaluate the clinical spectrum of patients with dystonia seen at Cleveland Clinic Abu Dhabi Hospital (CCAD), a tertiary care center…
  • 2023 International Congress

    Botulinum toxin injections for lingual protrusion dystonia: a review of the muscle target and dosage

    A. Duarte, H. Ghizoni Teive (Curitiba, Brazil)

    Objective: The aim of our study was to perform a literature review about the botulinum toxin types, their dosage and muscle target in the treatment…
  • 2023 International Congress

    Perception of the subjective visual vertical in subjects with cervical dystonia

    I. Reuter (Gießen, Germany)

    Objective: The Aim of the study was to assess:1.) if the perception of the visual vertical (VV) is impaired in subjects with cervical dystonia (CDsub),…
  • 2023 International Congress

    Quantifying the impact of sensory tricks on the overall severity of cervical dystonia

    A. Mahajan, D. Gonzalez, G. Stebbins, C. Comella (Chicago, USA)

    Objective: To quantify the impact of sensory trick on botulinum toxin dose and treatment outcomes in cervical dystonia (CD) Background: Sensory tricks are voluntary maneuvers…
  • 2023 International Congress

    Early-onset levodopa-responsive Parkinsonism associated with dysarthria, pyramidalism, and dystonia: a rare condition that can benefit from a combined treatment approach.

    L. Gallo, M. Avenali, P. Mitrotti, C. Tassorelli, R. Zangaglia, F. Valentino, S. Gana, EM. Valente, C. Pacchetti, G. Cosentino (Pavia, Italy)

    Objective: To describe a rare case of early-onset parkinsonism (EOP) successfully treated with a combined therapeutic approach. Background: EOP is a rare condition manifesting with…
  • 2023 International Congress

    The effect of botulinum toxin on anxiety in cervical dystonia.

    D. Sugar, R. Patel, C. Comella, D. Gonzalez, G. Gray, G. Stebbins, A. Mahajan (Chicago, USA)

    Objective: To assess the impact of botulinum toxin injections (BoNT) on anxiety symptoms and motor symptoms in cervical dystonia (CD) during one treatment cycle. Background:…
  • 2023 International Congress

    Ultra long-term outcome of deep brain stimulation (DBS) compared to botulinum toxin (BoNT) treatment in cervical dystonia (CD)

    IM. Wedding, V. Siewers, IM. Skogseid (Oslo, Norway)

    Objective: To compare residual symptoms and disease-specific quality of life (DS-QoL) in CD patients treated with DBS, or BoNT injections alone, for minimum 3 years.…
  • 2023 International Congress

    A Phase 2, Double-blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ABP-450 (PrabotulinumtoxinA) in Adults with Isolated Cervical Dystonia

    J. Jankovic, C. Oh, Y. Liu, C. Comella (Irvine, USA)

    Objective: To evaluate the safety and the efficacy of ABP-450 (prabotulinumtoxinA) in patients with cervical dystonia (CD). Background: ABP-450 (prabotulinumtoxinA) is a new 900kDA botulinumtoxinA.…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 21
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley